The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.
Degradation of several intracellular proteins involved in cell cycle control and tumour growth is regulated by the ubiquitin-dependent multicatalytic protease complex (proteasome). We report that proteasome inhibitor Z-Ile-Glu(OtBu)-Ala-Leucinal (PSI) was cytotoxic on most human myeloid leukaemia cell lines at IC50 doses ranging from 5 to 25 nmol/l. Additionally, PSI pre-treatment enhanced cytotoxicity by taxol and cisplatinum. PSI was more active on leukaemic than on normal CD34(+) bone marrow progenitors because the 50% growth inhibition of colony-forming unit granulocyte macrophage (CFU-GM) from cases of chronic myelogenous leukaemia (CML) and normal subjects was achieved by 15 nmol/l and 50 nmol/l PSI respectively. PSI killed cells by apoptosis as revealed by ultrastructural changes, nuclear DNA fragmentation, cleavage of poly (ADP-ribose) polymerase (PARP) and of beta-catenin, and was antagonized by ectopic expression of Bcl-2 but not by inactivating mutations of p53. This event was associated with a slight accumulation of Bcl-2, a decrease of Bax but no changes in Bcl-X(L) protein expression at any time point. In Ph(+) cell lines BCR-ABL protein was only down-regulated after 48 h of treatment with 10 nmol/l PSI. Altogether, these results indicate that PSI, alone or in association with other cytotoxic agents, has anti-tumour activity against myeloid malignancies and is more effective on leukaemic than on normal haematopoietic progenitor cells.
Soligo
D
D
Bone Marrow Transplantation Unit, I.R.C.C.S., Ospedale Maggiore and University of Milan, Italy. dsoligo@galactica.it
Servida
F
F
Delia
D
D
Fontanella
E
E
Lamorte
G
G
Caneva
L
L
Fumiatti
R
R
Lambertenghi Deliliers
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002461:Cell Line, Transformed; D002945:Cisplatin / Q000008:administration & dosage; D003598:Cytoskeletal Proteins / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D016044:Fusion Proteins, bcr-abl; D015870:Gene Expression / Q000187:drug effects; D019254:Genes, bcl-2; D016158:Genes, p53; D018922:HL-60 Cells / Q000187:drug effects / Q000648:ultrastructure; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000648:ultrastructure; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000032:analysis; D008854:Microscopy, Electron; D017239:Paclitaxel / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D015534:Trans-Activators; D051176:beta Catenin
C495270:CTNNB1 protein, human; D003598:Cytoskeletal Proteins; D008562:Membrane Glycoproteins; D011480:Protease Inhibitors; D015534:Trans-Activators; D051176:beta Catenin; C035766:leucinal; D016044:Fusion Proteins, bcr-abl; D007930:Leucine; D017239:Paclitaxel; D002945:Cisplatin